In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to HFA Silver & Gold Members, Fellows of the ESC and Young combined Members

Assessment of quality of life of patients followed in a heart failure clinic

Session Poster Session 2

Speaker Daniel Seabra

Event : Heart Failure 2019

  • Topic : cardiovascular nursing and allied professions
  • Sub-topic : Cardiovascular Nursing and Allied Professions - Other
  • Session type : Poster Session

Authors : P Silva (Penafiel,PT), D Seabra (Penafiel,PT), A Neto (Penafiel,PT), I Oliveira (Penafiel,PT), S Ferreira (Penafiel,PT), A Ferreira (Penafiel,PT), M Soares (Penafiel,PT), S Poaires (Penafiel,PT), M Meira (Penafiel,PT), A Andrade (Penafiel,PT)

Authors:
P Silva1 , D Seabra1 , A Neto1 , I Oliveira1 , S Ferreira1 , A Ferreira1 , M Soares1 , S Poaires1 , M Meira1 , A Andrade1 , 1Hospital Centre do Tamega e Sousa - Penafiel - Portugal ,

Citation:

Introduction: Heart failure (HF) is a disease with a major impact in patients (pts) quality of life (QoL). It affects psychological, physical and social domains. Kansas City Cardiomyopathy Questionnaire(KCCQ) is an internationally validated questionnaire that describes social and functional limitations and quantifies symptoms and signs of HF (frequency, severity and stability) and QoL in the previous 2 weeks. 

Aims: To assess the QoL of pts with chronic HF in a HF Clinic (HFC). 

Methods: Unicentric, retrospective analysis of pts followed in a HFC since 3/2011. Included pts with previous diagnosis of HF for at least 1 year, who completed the KCCQ. This questionnaire has 23 questions regarding 5 fields: physical function, symptoms (frequency, severity and recent change),social function, self-efficacy and knowledge, and QoL.

Results: The sample consists of 88 pts, with mean age of 60 years, 78.4% male. 65% had ischemic aetiology and 68.2% had HF hospitalization in the previous year. Regarding the questionnaire, 60% of pts had no physical limitation in self-care activities, 25% had moderate limitation in medium-effort activities and 25% felt slightly limited. 69.3% of pts had no HF symptoms in the previous 2 weeks. Those who were symptomatic (30.7%), the majority underestimated symptoms relevance (with 32% describing symptoms as "stable" and 13.6% stated as "feeling better"). 60% regarded themselves as "satisfied" if they had to spend the rest of their lives as they were at the time of the questionnaire. No significant limitation in daily life activity was experienced by 45% of pts. 30% rarely experienced disappointment symptoms regarding the illness. Only 20% knew exactly which factors might decompensate HF. 45.4% stated that HF symptoms did not limit their lives, and 30% usually did not experience depressive feelings about it. Social limitations were felt in 25.3% of pts.

Conclusion: KCCQ allows appropriate assessment of pts symptoms and functional implications in different areas, allowing the HFC team to improve pts well-being and provide knowledge to achieve a better understanding of their condition. In this cohort, most pts had no physical significant daily-life limitations and considered themselves "satisfied", which might reflect that they have a good QoL. However, it also shows that there is room to reinforce the nursing teaching sessions mainly about the factors that can decompensate their health status.

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are